Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(65)
Filter by content year
2024
(8)
2023
(8)
2022
(10)
2021
(14)
2020
(25)
Filter by form group
Filter by category
All
(65)
(-)
Clinical
(65)
(-)
Science
(65)
Collaborators
(47)
Other
(24)
Events
(3)
Filter by category
Search
News
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
News
Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein
News
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
News
Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren
News
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
News
Pfizer-BioNTech COVID-19-Impfstoff löst in vitro neutralisierende Antikörperantwort gegen SARS-CoV-2 mit einer Mutation aus, die mit einer schnellen Übertragung assoziiert wird
News
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
News
Pfizer und BioNTech veröffentlichen erste positive Daten zu mRNA-basiertem Hauptimpfstoffkandidaten BNT162b2 gegen COVID-19
News
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
News
BioNTech und Pfizer beginnen rollierenden Einreichungsprozess bei der europäischen Arzneimittelbehörde EMA für Impfstoffkandidaten BNT162b2 gegen SARS-CoV-2
Pagination
Previous page
‹‹
Page 2
Next page
››